Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID-2 durvalumab adjuvant therapy in MRD-positive resected stage II-III NSCLC
NL-OMON52301Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoint: Disease-free survival in the PD-L1 TC >=1% analysis set. Started Aug 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52301.